Nucleoprotein machines carry out essential biological processes including synthesis, modification, and repairof DNA and RNA. We propose to establish a nanomedicine development center (NDC) focusing on a modelnanomachine that carries out nonhomologous end joining (NHEJ) of DNA double strand breaks. This andother DNA repair machines have relatively simple structures (< 20 components) and significant biologicaland clinical relevance. DNA damage repair is vitally important to human health, as both normal metabolicactivities and environmental factors can cause DNA damage, resulting in as many as 100,000 individualmolecular lesions per cell per day. If allowed to accumulate without repair, these lesions interfere with genetranscription and replication, leading to premature aging, apoptosis, or unregulated cell division. We haveassembled an interdisciplinary team from eight institutions, with significant expertise in cell and molecularbiology of DNA damage repair, protein tagging and targeting, nanostructured probes, cryo-electronmicroscopy, signal-cell imaging, quantitative image analysis and computational biology, and light microscopyinstrumentation. We will develop innovative nanotechnologies and biomolecular approaches to elucidate thestructure-function relationships within and among DNA repair nanomachines. General principles emergingfrom these studies will lay a foundation for precise modification of the information stored in DNA and RNA,leading ultimately to novel therapeutic strategies for a wide range of diseases, including cancer. The NDChas five closely related aims including: (1) to develop orthogonal protein tagging strategies and novelfluorescence probes including quantum dot bioconjugates for nanomachine targeting; (2) to decipherstructure-function relationship of components required for the core NHEJ reaction; (3) to characterize thedynamics of nanomachine assembly and disassembly in the context of repair foci; (4) to determine thedimensions and structure of repair foci at high resolution in fixed cells; (5) to establish the engineering designprinciples underlying DNA double-strand break repair. This NDC will complement existing NDCs that focuson filaments, membranes and protein folding enzymes, and the probes, tools and methodologies developedwill be applicable to a wide range of biological and disease studies. Our long-term vision is to provide geneticcures for common human diseases based on the ability to manipulate the somatic human genome usingnanomedicine approaches that are inexpensive, effective, and user-friendly, similar to vaccination today.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Development Center (PN2)
Project #
7PN2EY018244-11
Application #
9076706
Study Section
Special Emphasis Panel (ZEY1-VSN (20))
Program Officer
Mckie, George Ann
Project Start
2006-09-30
Project End
2016-07-31
Budget Start
2015-04-01
Budget End
2016-07-31
Support Year
11
Fiscal Year
2014
Total Cost
$2,650,554
Indirect Cost
$342,073
Name
Rice University
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
050299031
City
Houston
State
TX
Country
United States
Zip Code
77005
Rao, Tata Nageswara; Gupta, Manoj K; Softic, Samir et al. (2018) Attenuation of PKC? enhances metabolic activity and promotes expansion of blood progenitors. EMBO J 37:
Jarrett, Kelsey E; Lee, Ciaran M; Yeh, Yi-Hsien et al. (2017) Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Sci Rep 7:44624
Bak, Rasmus O; Dever, Daniel P; Reinisch, Andreas et al. (2017) Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. Elife 6:
Lee, Ciaran M; Zhu, Haibao; Davis, Timothy H et al. (2017) Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells. Methods Mol Biol 1498:3-21
Lee, Ciaran M; Cradick, Thomas J; Bao, Gang (2016) The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells. Mol Ther 24:645-54
Porteus, Matthew (2016) Genome Editing: A New Approach to Human Therapeutics. Annu Rev Pharmacol Toxicol 56:163-90
Tabebordbar, Mohammadsharif; Zhu, Kexian; Cheng, Jason K W et al. (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351:407-411
Dever, Daniel P; Bak, Rasmus O; Reinisch, Andreas et al. (2016) CRISPR/Cas9 ?-globin gene targeting in human haematopoietic stem cells. Nature 539:384-389
Chew, Wei Leong; Tabebordbar, Mohammadsharif; Cheng, Jason K W et al. (2016) A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods 13:868-74
Rowe, R Grant; Wang, Leo D; Coma, Silvia et al. (2016) Developmental regulation of myeloerythroid progenitor function by the Lin28b-let-7-Hmga2 axis. J Exp Med 213:1497-512

Showing the most recent 10 out of 91 publications